Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2012 (2012), Article ID 265691, 12 pages
Review Article

Utilisation of Nanoparticle Technology in Cancer Chemoresistance

1Department of Pathology, Faculty of Medicine & Surgery, University of Malta, Msida MSD 2060, Malta
2School of Medicine, Kanazawa University Hospital, University of Kanazawa, Kanazawa 920-1192, Japan

Received 6 August 2012; Revised 11 October 2012; Accepted 11 October 2012

Academic Editor: Michele Caraglia

Copyright © 2012 Duncan Ayers and Alessandro Nasti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The implementation of cytotoxic chemotherapeutic drugs in the fight against cancer has played an invariably essential role for minimizing the extent of tumour progression and/or metastases in the patient and thus allowing for longer event free survival periods following chemotherapy. However, such therapeutics are nonspecific and bring with them dose-dependent cumulative adverse effects which can severely exacerbate patient suffering. In addition, the emergence of innate and/or acquired chemoresistance to the exposed cytotoxic agents undoubtedly serves to thwart effective clinical efficacy of chemotherapy in the cancer patient. The advent of nanotechnology has led to the development of a myriad of nanoparticle-based strategies with the specific goal to overcome such therapeutic hurdles in multiple cancer conditions. This paper aims to provide a brief overview and recollection of all the latest advances in the last few years concerning the application of nanoparticle technology to enhance the safe and effective delivery of chemotherapeutic agents to the tumour site, together with providing possible solutions to circumvent cancer chemoresistance in the clinical setting.